Page last updated: 2024-08-24

bepafant and Sarcoma, Kaposi

bepafant has been researched along with Sarcoma, Kaposi in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aglietta, M; Arese, M; Barra, L; Benelli, R; Bussolino, F; Ghigo, D; Montrucchio, G; Primo, L; Rola-Pleszczynski, MR; Sanavio, F	1
Albini, A; Biancone, L; Boccellino, M; Bussolati, B; Camussi, G; Cantaluppi, V; Conaldi, PG; Del Sorbo, L; Toniolo, A	1

Other Studies

2 other study(ies) available for bepafant and Sarcoma, Kaposi

Article	Year
Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. The Journal of clinical investigation, 1995, Volume: 96, Issue:2 Topics: Aged; Animals; Azepines; Base Sequence; Cell Line; Chemotaxis; Choriocarcinoma; Collagen; Culture Media, Conditioned; Cytokines; Dogs; Drug Combinations; Endothelium, Vascular; Female; Growth Substances; Humans; Interleukin-1; Laminin; Lymphoma, Large B-Cell, Diffuse; Macrophages; Male; Mice; Mice, Inbred DBA; Molecular Sequence Data; Neoplasm Proteins; Neovascularization, Pathologic; Platelet Activating Factor; Platelet Membrane Glycoproteins; Proteoglycans; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sarcoma, Kaposi; Skin Neoplasms; Thrombin; Triazoles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Umbilical Veins; Uterine Neoplasms	1995
Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. The American journal of pathology, 1999, Volume: 155, Issue:5 Topics: Azepines; Cell Movement; Diterpenes; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gene Products, tat; Ginkgolides; HIV-1; Humans; Lactones; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Pyridinium Compounds; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sarcoma, Kaposi; tat Gene Products, Human Immunodeficiency Virus; Triazoles; Tumor Cells, Cultured	1999

Article

Year

Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis.

The Journal of clinical investigation, 1995, Volume: 96, Issue:2

Topics: Aged; Animals; Azepines; Base Sequence; Cell Line; Chemotaxis; Choriocarcinoma; Collagen; Culture Media, Conditioned; Cytokines; Dogs; Drug Combinations; Endothelium, Vascular; Female; Growth Substances; Humans; Interleukin-1; Laminin; Lymphoma, Large B-Cell, Diffuse; Macrophages; Male; Mice; Mice, Inbred DBA; Molecular Sequence Data; Neoplasm Proteins; Neovascularization, Pathologic; Platelet Activating Factor; Platelet Membrane Glycoproteins; Proteoglycans; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sarcoma, Kaposi; Skin Neoplasms; Thrombin; Triazoles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Umbilical Veins; Uterine Neoplasms

1995

Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.

The American journal of pathology, 1999, Volume: 155, Issue:5

Topics: Azepines; Cell Movement; Diterpenes; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gene Products, tat; Ginkgolides; HIV-1; Humans; Lactones; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Pyridinium Compounds; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sarcoma, Kaposi; tat Gene Products, Human Immunodeficiency Virus; Triazoles; Tumor Cells, Cultured

1999